Generic drug
Estradiol / norethindrone price, strengths & recalls
Generic of Combipatch
Pharmacies pay $19.94 for 28 tablets of Estradiol / norethindrone pack this week, and from $16.72 to $59.83 across its 5 priced strengths and forms. 4 manufacturers make it. It has 4 recalls on record, none ongoing. Its official label last changed on June 1, 2026.
Generic- Fair cash price
- $33.43
- Strengths
- 5
- Makers
- 4
- Updated
- Nov 11
Estradiol / norethindrone price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| Pack | $0.7123 | $19.94 / 28 tablets |
| Pack | $0.5972 | $16.72 / 28 tablets |
| Mimvey pack | $0.5972 | $16.72 / 28 tablets |
| Lo 0.5/0.1 28 day pack | $0.7123 | $59.83 / 84 tablets |
| 1/0.5 28 day pack | $0.5972 | $50.16 / 84 tablets |
The lowest cost per tablet is pack at $0.5972. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Brand names of estradiol / norethindrone
A brand and its generic share the active ingredient; the generic is almost always far cheaper.
Supply status: shortages & recalls
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Estradiol / norethindrone
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use ESTRADIOL AND NORETHINDRONE ACETATE TABLETS safely and effectively. See full prescribing information for ESTRADIOL AND NORETHINDRONE ACETATE TABLETS.ESTRADIOL and NORETHINDRONE ACETATE tablets, for oral use Initial U.S. Approval: 1998
WARNING: CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA, BREAST CANCER, and ENDOMETRIAL CANCER
WARNING: CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA, BREAST CANCER, and ENDOMETRIAL CANCER
See full prescribing information for complete boxed warning
Estrogen Plus Progestin Therapy
● The Women's Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) (5.1)
● The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer (5.2)
● The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older (5.3)
● Do not use estrogen plus progestogen therapy for the prevention of cardiovascular disease or dementia (5.1, 5.3)
Estrogen-Alone Therapy
● There is an increased risk of endometrial cancer in a woman with a uterus who use unopposed estrogens (5.2)
● The WHI estrogen-alone substudy reported increased risks of stroke and DVT (5.1)
● The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older (5.3)
● Do not use estrogen-alone therapy for the prevention of cardiovascular disease or dementia (5.2, 5.3)
Estrogen Plus Progestin Therapy
Cardiovascular Disorders and Probable Dementia
The Women's Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogen (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo [see Warnings and Precautions (5.1), and Clinical Studies (14.5)].
The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age and older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions (5.3), Use in Specific Populations (8.5), and Clinical Studies (14.6)].
Do not use estrogen plus progestogen therapy for the prevention of cardiovascular disease or dementia [see Warnings and Precautions (5.1, 5.3), and Clinical Studies (14.5, 14.6)].
Breast Cancer
The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer [see Warnings and Precautions (5.2), and Clinical Studies (14.5)].
Only daily oral 0.625 mg CE and 2.5 mg MPA were studied in the estrogen plus progestin substudy of the WHI. Therefore, the relevance of the WHI findings regarding adverse cardiovascular events, dementia and breast cancer to lower CE plus other MPA doses, other routes of administration, or other estrogen plus progestogen products is not known. Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products. Discuss with your patient the benefits and risks of estrogen plus progestogen therapy, taking into account her individual risk profile.
Prescribe estrogens with or without progestogens at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
Estrogen-Alone Therapy
Endometrial Cancer
There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestogen to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding [see Warnings and Precautions (5.2)].
Cardiovascular Disorders and Probable Dementia
The WHI estrogen-alone substudy reported increased risks of stroke and DVT in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral CE (0.625 mg)-alone, relative to placebo [see Warnings and Precautions (5.1), and Clinical Studies (14.5)].
The WHIMS estrogen-alone ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age and older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions (5.3), Use in Specific Populations (8.5), and Clinical Studies (14.6)].
Do not use estrogen-alone therapy for the prevention of cardiovascular disease or dementia [see Warnings and Precautions (5.1, 5.3), and Clinical Studies (14.5, 14.6)].
Only daily oral 0.625 mg CE was studied in the estrogen-alone substudy of the WHI. Therefore, the relevance of the WHI findings regarding adverse cardiovascular events and dementia to lower CE doses, other routes of administration, or other estrogen-alone products is not known. Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products. Discuss with your patient the benefits and risks of estrogen-alone therapy, taking into account her individual risk profile.
Prescribe estrogens with or without progestogens at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
Recent major changes (as listed on the label)
RECENT MAJOR CHANGES
Warnings and Precautions, Malignant Neoplasms (5.2) 11/2023
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA020870 · Noven Pharms Inc
- First approved
- August 7, 1998 (28 years ago)
- Latest approved change
- February 15, 2024
- Approved label
- PDF, Feb 16, 2024
- Generic makers
- 4 approved generic applications on the market
Estradiol / norethindrone questions
How much does estradiol / norethindrone cost without insurance?
Pharmacies pay about $19.94 for 28 tablets of estradiol / norethindrone pack ($0.7123 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $33.43. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
What is the brand name of estradiol / norethindrone?
Estradiol / norethindrone is sold as Combipatch. The generic has the same active ingredient and usually costs far less.
Is estradiol / norethindrone in shortage?
No shortage is reported for estradiol / norethindrone right now. We check the national shortage list every day.
Has estradiol / norethindrone been recalled?
4 recalls on record, none ongoing. Recalls name specific lots - check yours.
When did the estradiol / norethindrone label last change?
The official label was last updated on June 1, 2026 (version 5). See what changed.
Talk about estradiol / norethindrone
No comments yet. Questions, tips, what worked for you - start the conversation.